159 results about "Ophthalmological disorder" patented technology

Provided by the present invention are compositions or formulations suitable for application to a patient's eyes which utilizes a topical ophthalmically-acceptable formulation comprising a therapeutically-effective amount of an ophthalmically-active antimicrobial agent, and an ophthalmically-active anti-inflammatory or steroidal agent in combination with physiologic levels of serum electrolytes in an ophthalmic formulation for the treatment of changes in the normal eye condition. The invention also includes methods of treating patient's having an ophthalmic disease, injury or disorder, utilizing the compositions or formulations. Also provided are kits comprising the compositions or formulations and a means of applying the compositions or formulation to the patient's eyes.

Disclosed herein are systems, methods, and devices for classifying ophthalmic images according to disease type, state, and stage. The disclosed invention details systems, methods, and devices to perform the aforementioned classification based on weighted-linkage of an ensemble of machine learning models. In some parts, each model is trained on a training data set and tested on a test dataset. In other parts, the models are ranked based on classification performance, and model weights are assigned based on model rank. To classify an ophthalmic image, that image is presented to each model of the ensemble for classification, yielding a probabilistic classification score—of each model. Using the model weights, a weighted-average of the individual model-generated probabilistic scores is computed and used for the classification.

The present invention provides a method of treatment of an individual with an ophthalmic condition that may comprise the step of: administering to the individual a therapeutically effective amount of a compound capable of modulating the activity of mineralocorticoid receptors within cells or tissue located in an eye or adjacent to an eye in the individual to be treated. Preferably, said compound may be an anti-oedematous steroid, more preferably a mineralocorticoid.

The invention provides methods and compositions for the delivery of lipophilic drugs that are useful for the treatment of various ophthalmological diseases, disorders, and pathologies, including the treatment of age-related macular degeneration, diabetic retinopathy, diabetic macular edema, cancer, and glaucoma.

Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the pharmaceutical compositions such as hyaluronase allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met. The present invention also provides for kits, which contain molding contact lenses, pharmaceutical composition suitable for delivery to the eye, and instructions, useful in the inventive system.

A composition for treating or reducing a dry eye condition or an ophthalmological disorder that has an etiology in inflammation comprises a dissociated glucocorticoid receptor agonist (“DIGRA”). The composition can be formulated for topical application, injection, or implantation.

The invention describes compositions and kits comprising at least one organic nitric oxide enhancing salt of an angiotensin π antagonist, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The organic nitric oxide enhancing compounds that form salts with the angiotensin II antagonists are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.

The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one nitric oxide enhancing group, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; Q) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The cardiovascular compounds are angiotensin II antagonists, aldosterone antagonists, endothelin antagonists, hydralazine compounds, neutral endopeptidase inhibitors and renin inhibitors. The nitric oxide enhancing groups are nitroxides and/or heterocyclic nitric oxide donors.

Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.

The invention provides a target classification system. The target classification system can specifically be a knowledge data and artificial intelligence driven multi-disease identification system. The system can be used for: acquiring medical images and non-image medical information; using a medical expert knowledge base for matching information data, and obtaining an ophthalmic disease weight result through a medical knowledge reasoning algorithm; obtaining an ophthalmic disease weight result by using an organ tissue segmentation algorithm and a disease focus recognition algorithm in medical image diagnosis; obtaining weight results by combining knowledge reasoning and medical image recognition, and obtaining a final disease diagnosis result through weighted calculation. According to a medical clinical diagnosis thought, structured processing is carried out on medical data through big data, and automatic diagnosis of diseases is realized through the detection capability of an artificial intelligence model on disease focuses. The system improves the existing doctor seeing mode, realizes artificial intelligence preliminary diagnosis and screening of diseases, effectively relieves the current situation of shortage of medical resources, and has a wide application prospect.

The invention relates to application of carnosic acid in preparing a medicament for suppressing angiogenesis. The invention has the advantages that: the novel application of the carnosic acid discovers the effect of the carnosic acid in resisting angiogenesis for the first time, and the carnosic acid can effectively suppress proliferation, migration and canaliculization of vascular endothelial cells for the first time, which proves that the carnosic acid has the activity of resisting the angiogenesis, can be used as an angiogenesis suppressant, and can be applied to preparation of angiogenesis medicaments as the angiogenesis suppressant to treat neovascularization dependent and neovascularization related diseases, such as tumors, arthritis, psoriasis, ocular diseases, atherosclerosis, and the like.

The invention provides a multi-modal multi-disease long-tail distribution ophthalmic disease classification model training and recognition method and device, and relates to the technical field of deep learning, and the method comprises the steps: obtaining a bimodal image sample, and carrying out the marking of a diagnosis label for the bimodal image sample; inputting the infrared macular region fundus image sample and the OCT image sample into a first neural network at the same time for training to obtain first image feature information and second image feature information; calculating total image feature information according to the first image feature information, the first weight, the second image feature information and the second weight, and inputting the total image feature information into a full-connection network to obtain a prediction result; and continuously adjusting neural network parameters through a back propagation technology until an error value is maintained at a preset threshold value, and generating an ophthalmic disease classification model. Therefore, two modal image features are learned through a two-way convolutional neural network model to obtain a deep learning model similar to a clinical diagnosis process.

The invention provides a pH-sensitive conjugate with a high signal activation effect, micelle, and a preparation method and application thereof. The pH-sensitive conjugate comprises a hydrophilic chain segment and a hydrophobic chain segment, wherein the hydrophilic chain segment is mainly a strongly hydrophilic polymer such as polyethylene glycol, and the hydrophobic chain segment is a polyalkylaminoacrylate having a tertiary amino structure as shown in the formula 1, wherein each symbol is as defined in the specification. The hydrophobic chain segment contains marker molecules. By modifyingthe hydrophobic chain segment of the polymer with the marker molecules, the pH response activation of photodynamic effect can be realized and the phototoxicity to normal tissues can be reduced. In addition, the invention also provides the application of the pH-sensitive conjugate and micelle in photodynamic therapy of tumors, skin diseases and ophthalmic diseases and in combination with photothermal therapy, chemotherapy and immunotherapy.

The invention belongs to the field of brewing, and relates to a vinegar beverage capable of improving eyesight and refreshing oneself. The vinegar beverage is prepared from 1-4 parts of blueberries, 1-2 parts of dendrobium candidum, 1-2 parts of coreopsis tinctoria flowers, 6-8 parts of Chinese wolfberry fruits, 1-4 parts of semen cassiae, 10-26 parts of lotus leaves, 3-5 parts of smoked plums, 3-4 parts of poria cocos, 3-6 parts of tuber fleeceflower roots, 6-8 parts of black beans, 2-4 parts of mulberries, 1-2 parts of taurine, 1-2 parts of xanthophyll and 100-150 parts of millet vinegar. Based on a secret recipe handed down from generations, the inventor of the vinegar beverage combines the summary of clinical experience for many years and performs repeated experiments to obtain the vinegar beverage; therefore, the vinegar beverage has a unique treatment effect on ophthalmic diseases including refractory asthenopia and the like; through scientific concerted application of multiple medicines and comprehensive treatment, effective components of medicines rapidly enter blood circulation, so that eye diseases can be recovered quickly. The vinegar beverage disclosed by the invention also has a unique treatment effect on myopia, retinopathy and diabetic fundus diseases, and has the advantages of taking effect quickly, and being short in treatment course, high in cure rate and small in fees.

The invention relates to application of total triterpenes in preparing drugs inhibiting angiogenesis. The application has the advantages that novel application of the total triterpenes in extractive of Actinidia chinensis roots is provided. An experiment proves that the total triterpenes 1,2,3,4 have remarkable inhibiting effect on multiplication of human umbilical vein endothelial cells (HUVEC) and canaliculization of HUVEC, have anti-angiogenic activity, and can serve as angiogenesis inhibitors. By means of the application of the total triterpenes in preparing the drugs inhibiting the angiogenesis, the anti-angiogenesis effect of the total triterpenes in the extractive of Actinidia chinensis roots is firstly found out, and the total triterpenes can serve as the angiogenesis inhibitors to be applied to treat new blood vessel dependence and new vessel related diseases including tumors, arthritis, skin and eye diseases, atherosclerosis and the like.

The invention discloses a construction method, a construction kit and an application of an optic atrophy animal model, and relates to the biotechnical field. The construction method is characterized in that a base at the 277th locus of an exon 2 of an animal OPA3 gene mutates from G to A to cause missense mutation, an amino acid residue mutating from G to S, of the 93rd position of an encoded OPA3protein, and an animal containing the mutation exhibits typical optic atrophy disease characteristics and can be used as the optic atrophy animal model. The animal model fills a gap in human autosomal dominant optic atrophy animal models, enriches the type of existing optic atrophy animal models, and facilitates the development of researches on ophthalmic diseases.